Turnhout, Belgium (ots/PRNewswire) - Movetis NV, a European specialist pharmaceutical company, today announced that M0002 is progressing to phase IIb following positive results of a phase IIa multiple-dosing trial for the treatment of ascites, the accumulation of fluid in the abdomen in patients with liver ...
Turnhout, Belgium (ots/PRNewswire) - - New Generation Compound Provides Significant Benefit in Patients who do not Adequately Respond to Laxatives New phase III data for RESOLOR(R) (prucalopride) published today in The New England Journal of Medicine (NEJM) shows statistically and clinically significant improvement of bowel function and reduced severity of ...
Turnhout, Belgium (ots/PRNewswire) - Movetis today announced that the European Medicines Agency (EMeA) has accepted the Marketing Authorization Application (MAA) submission for RESOLOR(R) (prucalopride) as a treatment for chronic constipation in adults in whom laxatives fail to provide adequate relief. RESOLOR is a new selective, high affinity 5-HT4 receptor ...
Paris (ots/PRNewswire) - - Novel Compound Offers Hope to Patients not Adequately Responding to Laxative Treatment Data presented for the first time today at the international gastroenterology meeting UEGW (United European Gastroenterology Week) confirm the effectiveness and safety of RESOLOR(R) ...